Drug intelligence / Profile preview

Weikang

Development stage: Preclinical
Lead developer: Weikang Bio-Technology Group
Administration: Oral

Overview

Weikang is a product, likely a traditional medicine or dietary supplement, that has been investigated in clinical trials for various conditions. It has been studied in the form of "Weikang Capsule" for aspirin-related gastric and small intestinal mucosal injury, and as "weikang-granula" for suboptimal health status. When combined with selenium ("selenium weikang"), it was observed to decrease serum arsenic and increase serum selenium and copper, leading to improvements in appetite and memory in patients with schizophrenia.

Other names: Weikang Capsuleweikang-granula

Beyond the preview

Go deeper on Weikang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weikang.

Explore the full profile